Abstract:Abstract Background The incidence of carbapenem-resistant organisms (CROs) has increased over the past 3 decades. Carbapenem-resistance due to metallo-β-lactamases (MBLs) such as the Verona integron-encoded metallo-β-lactamase (VIM) are particularly problematic due to the limited treatment options. We describe a multi-species outbreak of VIM-producing CROs (VIM CROs) in a tertiary care hospital along with our experience using novel β-lactam antibiotics for treatment. Methods We performed a retrospective chart review after a cluster of patients in the burn unit of a tertiary care hospital were found to have infections with VIM CROs. Electronic medical records for all patients with a VIM CRO isolated between November 2021 and March 2022 were reviewed. Data regarding patient characteristics, antimicrobial use, culture results, antimicrobial susceptibility testing, and clinical outcomes were recorded for each patient. Results 8 patients were found to have VIM-mediated CRO burn wound infections, 5 of whom were also bacteremic with a VIM CRO. A VIM gene was identified in 5 different species (Pseudomonas aeruginosa and 4 Enterobacterales). None of the patients received carbapenems prior to isolation of a CRO. Among the 5 patients treated with cefiderocol, 2 had cefiderocol-resistant VIM CROs isolated 10-20 days after starting cefiderocol. 3 patients received the combination of ceftazidime/avibactam and aztreonam, and all had subsequent clearing of their CRO infection on follow-up cultures taken from the same site. Only one of the 8 patients died within 30 days of initial CRO isolation, after developing a subsequent fungal infection. The median Pitt bacteremia score at the time of initial CRO isolation was 1 (range 0-4) in the 7 patients who survived versus a score of 6 in the patient who died. Conclusion MBLs such as VIM have the potential for multi-species spread throughout hospital units even in the absence of carbapenem selection pressure. Although over 60% of the patients in this study had bacteremia and cefiderocol-resistance developed in 40% of the patients treated with cefiderocol, mortality was fortunately low in this group. While newer β-lactam antibiotics remain an exciting addition to our armamentarium, we must remain diligent in monitoring for rapid development of resistance. Disclosures Thomas R. Talbot, III, MD, MPH, OmniSolve: Board Member Romney Humphries, PhD, D(ABMM), M(ASCP), Accelerate: Advisor/Consultant|Accelerate: Stocks/Bonds|bioMerieux: Advisor/Consultant|IHMA: Advisor/Consultant|Pattern: Advisor/Consultant|Qiagen: Advisor/Consultant|QPex: Advisor/Consultant|Roche: Advisor/Consultant|Specific Diagnostics: Advisor/Consultant|Specific Diagnostics: Stocks/Bonds|ThermoFisher: Advisor/Consultant|Torus: Advisor/Consultant.

Concurrent transmission of multiple carbapenemases in a long-term acute-care hospital

Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a chinese hospital

Infections Caused by Carbapenemase-Producing Klebsiella Pneumoniae: Microbiological Characteristics and Risk Factors

Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital

Genomic epidemiology and longitudinal sampling of ward wastewater environments and patients reveals complexity of the transmission dynamics of bla KPC-carbapenemase-producing Enterobacterales in a hospital setting

bla KPC and rmtB on a single plasmid in Enterobacter amnigenus and Klebsiella pneumoniae isolates from the same patient

Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination

A multi-species outbreak of VIM-producing carbapenem-resistant bacteria in a burn unit and subsequent investigation of rapid development of cefiderocol resistance

Identification of Plasmid-Mediated Carbapenem-Hydrolyzing Β-Lactamase KPC-2 in Enterobacteriaceae

Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-β-lactamase (blaVIM): infection management and molecular analysis

Integrated analysis of patient networks and plasmid genomes reveals a regional, multi-species outbreak of carbapenemase-producing Enterobacterales carrying both bla IMP and mcr-9 genes

Molecular characterization and antibiogram of the carbapenemase gene variants in clinical strains of Pseudomonas aeruginosa

Concurrence of Porin Loss and Modular Amplification of β-Lactamase Encoding Genes Drives Carbapenem Resistance in a Cohort of Recurrent Enterobacterales Bacteremia

Coexistence of seven different carbapenemase producers in a single hospital admission screening confirmed by whole-genome sequencing

Acquired blaVIM and blaGES Carbapenemase-Encoding Genes in Pseudomonas aeruginosa: A Seven-Year Survey Highlighting an Increasing Epidemiological Threat

An outbreak of double carbapenemase-producing Klebsiella pneumoniae, harbouring NDM-5 and OXA-48 genes, at a tertiary hospital in Canberra, Australia

Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): a new epidemiologic scenario

Covert dissemination of carbapenemase-producing Klebsiella pneumoniae (KPC) in a successfully controlled outbreak: long- and short-read whole-genome sequencing demonstrate multiple genetic modes of transmission

Successful Control of an Outbreak of Klebsiella pneumoniae Carbapenemase—Producing K. pneumoniae at a Long-Term Acute Care Hospital

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China

672. Report of a Multi-species Outbreak of VIM-producing Carbapenem-resistant Organisms in a Burn Unit and Subsequent Experience Using Novel Β-Lactam Antibiotics for Treatment